Hims & Hers Faces Multifaceted Challenges as Investor Confidence Wavers

Hims & Hers shares fell 5% as JPMorgan slashed its stake, a board probe began, and its pivot to lower-margin brand-name drugs led to disappointing guidance.

Shares of telehealth company Hims & Hers Health Inc. declined nearly 5% on Tuesday, closing around $22, as the firm navigates a confluence of legal, institutional, and financial headwinds.

Regulatory Scrutiny and a Major Institutional Exit

A significant reduction in stake by JPMorgan Chase has shaken institutional confidence. The bank slashed its holding in Hims & Hers from 8.1% to 1.7%, marking a substantial withdrawal of support.

This move coincides with a board-level investigation initiated by shareholder rights law firms. The probe, prompted by a New York Times report, is examining whether the company's directors provided adequate oversight during the shift in its weight management segment toward GLP-1 medications. The report had raised questions about the legal and clinical foundations of the marketing for weight-loss treatments.

Profitability Concerns and Disappointing Guidance

A wave of analyst price target cuts followed the company's recent updates. Evercore ISI reduced its target to $24 from $33, with similar downward revisions from Citi, Truist, and Morgan Stanley.

The core financial issue stems from a strategic pivot. Hims & Hers is transitioning from compounded alternatives to brand-name drugs like Wegovy and Ozempic, facilitated by a partnership with Novo Nordisk established in early March. This shift inherently carries lower margins. The company's revenue forecast for the first quarter of 2026, set between $600 million and $625 million, fell notably short of the analyst consensus estimate of $652 million.

Compliance Headwinds and Insider Transaction

The regulatory environment for telehealth is becoming more stringent. On March 3, 2026, the U.S. Food and Drug Administration (FDA) issued 30 warning letters to telehealth companies concerning misleading statements about compounded GLP-1 drugs. While Hims & Hers has begun migrating its subscribers to FDA-approved medications, the associated compliance costs are weighing on its valuation.

Adding to the cautious market sentiment was a stock sale by Chief Financial Officer Oluyemi Okupe. On March 20, under a pre-arranged trading plan, he divested 9,217 shares at prices ranging from $23.73 to $23.92. Although the transaction was formally compliant, its timing has amplified investor unease.

As the first-quarter earnings report approaches, market participants will focus intently on two key metrics: subscriber growth trends and the long-term trajectory of EBITDA margins under the new brand-name drug strategy.